Evommune, Inc. ( EVMN ) Discusses In Licensing of EVO570 for Autoimmune Diseases November 5, 2026 8:30 AM EST
Company Participants
Luis Peña - Founder, President, CEO & Director
Gregory Moss - Chief Business & Legal Officer, Corporate Secretary and Chief Compliance Officer
Jeegar Patel - Chief Scientific Officer
J. Jackson - Senior Vice President of Clinical Development
Presentation
Luis Peña
Founder, President, CEO & Director
Good morning, and thank you for joining us. I'm Luis Pena, the President and CEO of Evommune. Yesterday, we announced our agreement with Hinova for global development rights, excluding Greater China to EVO570, an oral VAV1 molecular glue degrader. Over the next few minutes, we'll explain why we did this deal, what the science shows and how EVO570 fits into the rest of our portfolio. I'm joined today by Greg Moss, our Chief Business and Legal Officer, who will cover the deal terms and the competitive landscape.…